By Adam Bonislawski

December 21, 2016 

NEW YORK (GenomeWeb) – Nuclea Biotechnologies is auctioning its assets as part of Chapter 7 bankruptcy proceedings.

Heritage Global Partners will manage the auction, set for Jan. 18, 2017. The sale will include Nuclea’s intellectual property and other assets such as its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer that overexpressed the HER2/neu protein.

Nuclea filed a voluntary Chapter 7 petition in US Bankruptcy Court for the District of Delaware on Aug. 30, 2016. According to filings, the company had at that time $235,144 in assets and debts of $9.6 million… Read Full Story on